Non-Hodgkin lymphoma is a type of cancer that affects the lymphatic system – the network of vessels, nodes, and organs that help the body fight off infections and diseases.

It is the sixth most common cancer in the United States, accounting for 4% of all cancer cases in the country. Although the disease can be treated with various therapies such as chemotherapy, radiation, and immunotherapy, the side effects can be debilitating for patients.

In recent years, a new treatment approach has emerged – subcutaneous formulation for non-Hodgkin lymphoma.

What is subcutaneous formulation?

Subcutaneous formulation is a method of administering medication directly under the skin, unlike traditional methods that involve intravenous injection or oral medication.

The medication is injected into the fatty tissue (subcutaneous tissue) located between the skin and the muscle. Subcutaneous formulation allows for a greater concentration of the drug to be delivered directly to the site of the disease, enhancing the efficacy of the medication while reducing the side effects.

Why is subcutaneous formulation a breakthrough treatment approach?

Subcutaneous formulation has several benefits over traditional methods of administering medication:.

Less painful and invasive
Less time-consuming
Allows for self-administration in some cases
Reduces the risk of infection and other complications associated with intravenous injection

Moreover, subcutaneous formulation has been shown to be just as effective as intravenous administration while reducing the occurrence of side effects.

Clinical trials have demonstrated that subcutaneous formulations for non-Hodgkin lymphoma are well-tolerated by patients and provide similar outcomes in terms of efficacy and safety.

What are the subcutaneous formulations available for non-Hodgkin lymphoma?

There are several subcutaneous formulations available for the treatment of non-Hodgkin lymphoma, including:.

Rituximab – an immunotherapy drug that targets specific proteins on the surface of cancer cells, causing them to self-destruct
Abraxane – a chemotherapy drug that works by interfering with the growth and division of cancer cells
Bortezomib – a targeted therapy drug that inhibits the growth and replication of cancer cells

These medications are used either alone or in combination with other treatments such as chemotherapy or radiation therapy.

How is subcutaneous formulation administered?

Subcutaneous formulation can be administered in a few different ways, depending on the medication being used:.

Using a pre-filled syringe
Using a pre-filled pen injector
Using an automated pump that delivers a continuous infusion over a set time period

Patient education and training are essential for the safe and successful administration of subcutaneous formulations.

Patients must receive proper instruction on how to handle and administer the medication, as well as how to identify and manage any potential side effects.

What are the side effects of subcutaneous formulations for non-Hodgkin lymphoma?

Subcutaneous formulations for non-Hodgkin lymphoma are generally well-tolerated by patients, with fewer side effects than traditional intravenous administration. However, some common side effects may include:.

Fatigue
Nausea
Diarrhea
Fever
Headache

Patients should consult with their healthcare provider if they experience any side effects, as they may require medical attention.

Conclusion

Subcutaneous formulation is a promising treatment approach for non-Hodgkin lymphoma, offering several benefits over traditional intravenous methods.

It allows for greater efficacy of medication while reducing the occurrence of side effects, resulting in better quality of life for patients. As with any medical treatment, patients should consult with their healthcare provider to determine if subcutaneous formulation is an appropriate option for them.